SJSøren Jensen-Fangel

Søren Jensen-Fangel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Søren Jensen-Fangel has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Axel Møller

    From the aDepartment of Infectious Diseases and bDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, the cDepartment of Infectious Diseases, Odense University Hospital, Odense, the dDepartment of Infectious Diseases, Aalborg Hospital, Aalborg, the eDepartment of Infectious Diseases, Herning Hospital, Herning and the fDepartment of Infectious Diseases, Kolding Hospital, Kolding, Denmark

    6 shared publications
  • Palle Tauris

    From the aDepartment of Infectious Diseases and bDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, the cDepartment of Infectious Diseases, Odense University Hospital, Odense, the dDepartment of Infectious Diseases, Aalborg Hospital, Aalborg, the eDepartment of Infectious Diseases, Herning Hospital, Herning and the fDepartment of Infectious Diseases, Kolding Hospital, Kolding, Denmark

    6 shared publications
  • Court Pedersen

    Department of Infectious Diseases, Odense University Hospital, Odense, Denmark

    5 shared publications
  • Henrik Toft Sørensen

    Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University Hospital and Aarhus University, Denmark

    4 shared publications
  • Court Pedersen

    From the aDepartment of Infectious Diseases and bDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, the cDepartment of Infectious Diseases, Odense University Hospital, Odense, the dDepartment of Infectious Diseases, Aalborg Hospital, Aalborg, the eDepartment of Infectious Diseases, Herning Hospital, Herning and the fDepartment of Infectious Diseases, Kolding Hospital, Kolding, Denmark

    3 shared publications
  • Niels Obel

    From the aDepartment of Infectious Diseases and bDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, the cDepartment of Infectious Diseases, Odense University Hospital, Odense, the dDepartment of Infectious Diseases, Aalborg Hospital, Aalborg, the eDepartment of Infectious Diseases, Herning Hospital, Herning and the fDepartment of Infectious Diseases, Kolding Hospital, Kolding, Denmark

    3 shared publications

Latest Publications

  • Open Access

    Adherence to the cervical cancer screening program in women living with HIV in Denmark: comparison with the general population

    by Kristina Thorsteinsson, Steen Ladelund, Søren Jensen-Fangel, Terese L Katzenstein, Isik Somuncu Johansen, Gitte Pedersen, Jette Junge, Marie Helleberg, Merete Storgaard, Anne-Mette Lebech

    Women living with HIV (WLWH) are at increased risk of invasive cervical cancer (ICC). International HIV guidelines suggest cervical screening twice the first year after HIV diagnosis and thereafter annually. Adherence to the HIV cervical screening program in Denmark is unknown.


  • Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial

    by Ann-Brit Eg Hansen, Jan Gerstoft, Ole Kirk, Lars Mathiesen, Court Pedersen, Henrik Nielsen, Søren Jensen-Fangel, Henrik Toft Sørensen, Niels Obel


  • Gender differences in hospitalization rates for respiratory tract infections in Danish youth

    by Søren Jensen-Fangel, Rajesh Mohey, Søren P Johnsen, Paul Lehm Andersen, Henrik Toft Sørensen, Lars Østergaard

    Overall morbidity and mortality rates in childhood are reported to be higher in males than females. As respiratory tract infections constitute the leading cause of childhood hospitalization, we examined the gender difference in rates of hospitalization due to respiratory tract infections in Danish youth (under age 25). We studied a total of 64,049 hospitalizations for otitis media, pneumonia, influenza, and other acute respiratory tract infections from 1995 to 1999, with calculation of hospitalization rates by age and gender. The male-female hospitalization rate ratio (HRR) for admission due to a respiratory tract infection decreased from 1.45 (95% confidence interval (CI) 1.42–1.48) in the age group 0 –<5 y, to 1.62 (95% CI 1.55–1.70) in the age group 5 –<10 y, 1.13 (95% CI 1.04–1.22) in the age group 10 –<15 y, 0.83 (95% CI 0.76–0.90) in the age group 15 –<20 y, and 0.87 (95% CI 0.80–0.95) in the age group 20 –<25 y. In young children, boys were hospitalized more often than girls, but the reverse applied in children and adolescents 15–25 y of age. The study generates the hypothesis that gender plays a role in the susceptibility for respiratory infections in early childhood.


  • Low mortality in HIV-infected patients starting highly active antiretroviral therapy

    by Søren Jensen-Fangel, Lars Pedersen, Court Pedersen, Carsten S Larsen, Palle Tauris, Axel Møller, Henrik T Sørensen, Niels Obel

    Objectives: To assess the mortality in a cohort of HIV-infected patients starting highly active antiretroviral therapy (HAART) compared to the mortality of the general population, focusing on the influence of the CD4 cell count at the time of starting HAART. Methods: Patients in the HIV Cohort Study in Western Denmark starting HAART before 1 January 2002 were identified. For each patient, 100 population controls matched on age and gender were extracted from the Danish Civil Registration System. Mortality rates were compared between the two cohorts overall, and in four groups defined by baseline CD4 cell counts. Results: A total of 647 HIV-infected patients and 64 700 population controls were included, accounting for 53 and 815 deaths during follow-up. In the HIV group, mortality rates were 70.0 per 1000 person-years at risk in the lowest CD4 cell group (< 50 × 106 cells/l), and 3.2 in the highest (≥ 200 × 106 cells/l). Compared with population controls, mortality rate ratios declined with increasing CD4 cell counts, being 15.3 [95% confidence interval (CI), 9.8–23.8], 8.6 (95% CI, 4.3–16.8), 5.9 (95% CI, 3.0–11.4), and 3.6 (95% CI, 2.0–6.5) in the groups with CD4 cell count < 50, 50–99, 100–199, and ≥ 200 × 106 cells/l. Conclusion: In comparison with the general population, HIV-infected patients starting HAART with a CD4 cell count above 200 × 106 cells/l had low mortality rates that were comparable with the rates found in other chronic medical diseases. The mortality rates increased considerably when treatment was started at lower baseline CD4 cell counts.


  • Use of the Protease Inhibitor Saquinavir Hard Gel in Human Immunodeficiency Virus-infected Patients in the Early Period of Highly Active Antiretroviral Therapy: Does it Affect Long-term Treatment Outcome?

    by Søren Jensen-Fangel, Court Pedersen, Henrik Nielsen, Palle Tauris, Axel Møller, Henrik Toft Sørensen, Niels Obel

    Saquinavir hard gel capsule (hgc), the first human immunodeficiency virus (HIV) protease inhibitor (PI) used in clinical practice, has been shown to have insufficient effectiveness. A population-based cohort study assessed the long-term consequences of using saquinavir hgc as initial PI in HIV-infected patients pre-exposed to nucleoside reverse transcriptase inhibitors. 121 patients starting a regimen with saquinavir hgc were compared with 91 starting with non-boosted indinavir (n = 72) or ritonavir (n = 19). Median follow-up time was 4.6 and 4.7 y for the 2 groups. Starting with saquinavir hgc was associated with a lower overall probability of achieving an undetectable viral load [risk ratio (RR) = 0.41, 95%, confidence interval (95% CI) 0.30-0.56]. However, the lower probability of having undetectable viral load during follow-up declined over time with odds ratios (OR) = 0.27 (95%, CI 0.14-0.54), 0.35 (951% CI 0.19-0.66), 0.47 (95% CI 0.24-0.91) and 0.73 (95% CI 0.34-1.55) at 60, 120, 180 and 240 weeks, respectively, after starting HAART. Starting with saquinavir hgc was correlated with a higher risk of having the initial PI discontinued (RR = 1.89, 95% CI 1.39-2.58). The insufficient suppression of viral load in patients starting with saquinavir hgc subsided during follow-up, probably owing to the earlier discontinuation of saquinavir hcg in favour of newer and more potent HAART regimens.


  • Open Access

    The use of calcium carbonate in nelfinavir‐associated diarrhoea in HIV‐1‐infected patients

    by S Jensen‐Fangel, Us Justesen, Ft Black, C Pedersen, N Obel

    Objectives: To evaluate the efficacy of oral calcium supplements in HIV‐infected patients with nelfinavir (NFV)‐associated diarrhoea, and to investigate the influence on the pharmacokinetics of nelfinavir and the active metabolite M8.Methods: An open‐label prospective trial with enrolment of 15 patients with NFV‐associated diarrhoea. Study subjects received either calcium carbonate or calcium gluconate/calcium carbonate in addition to highly active antiretroviral therapy (HAART), and were randomized to (i) calcium supplements for 14 days followed by 14 without calcium supplements, or (ii) 14 days without calcium supplements followed by calcium supplements for 14 days. Clinical endpoint was the severity of diarrhoea, graded and summarized for the specific 14 day‐period. In the pharmacokinetic evaluation concentrations of NFV and M8 were measured before morning dosing, and 3 h after dosing.Results: Nine patients were treated with calcium carbonate, and six with calcium gluconate/calcium carbonate. In the paired analysis, neither of the groups had a significant improvement in diarrhoea score when treated with calcium supplements (P = 0.34 and 0.46, respectively). We found no significant differences in the concentrations of NFV and M8 between the calcium and control periods.Conclusions: Oral calcium supplements did not significantly improve nelfinavir‐associated diarrhoea. In the pharmacokinetic analysis calcium supplements did not induce major alterations in plasma concentrations of NFV and M8.


  • Open Access

    The Effect of Race/Ethnicity on the Outcome of Highly Active Antiretroviral Therapy for Human Immunodeficiency Virus Type 1–Infected Patients

    by Søren Jensen‐Fangel, Lars Pedersen, Court Pedersen, Carsten Schade Larsen, Palle Tauris, Axel Møller, Henrik Toft Sørensen, Niels Obel

    We performed a population-based cohort study to assess the impact of nonwhite origin on the outcome of highly active antiretroviral therapy (HAART) for a Danish cohort of human immunodeficiency virus (HIV)-infected patients. A total of 389 whites and 135 nonwhites started receiving HAART before 1 April 2001. After 1 year of treatment, 78% of nonwhites and 76% of whites achieved a virus load of + cell count. One year after fulfilling Danish recommendations for initiation of HAART, 91% of nonwhites and 93% of whites had started receiving HAART. Race and ethnic origin play no major role in the outcome associated with HAART if access to health care is free.


    • 19 August 2002
      • Vol. 164  (34) , 3964-7

    [HIV in Western Denmark. Demographic data from a population-based cohort study].

    by Søren Jensen-Fangel, Court Pedersen, Carsten Schade Larsen, Palle Tauris, Axel Møller, Niels Obel

    The course of HIV infection has changed since the introduction of highly active anti-retroviral treatment. We present demographic data from an observational database on HIV and AIDS in the Western part of Denmark, a region representing 2,935,156 individuals, or 55.1% of the population in Denmark (1 January 2000). Five centres in the region treat HIV positive adults; all patients attached to these centres since 1995 are included. Altogether 749 adult HIV-infected individuals were enrolled as of 31 December 1999. Estimates of the prevalence and incidence of HIV infection in the area were 25.8/100,000 and 2.6/100,000 respectively, which are lower than the average for the country. The number of newly diagnosed HIV-infected patients remained constant in the period 1995-1999 with an average of 62 diagnoses per year. The number of HIV-related deaths declined from 43 in 1995 to 15 in 1999. There seems to be a shift in the HIV epidemic over the last few years, with a higher proportion of newly diagnosed HIV-patients who have contracted the infection through heterosexual contact, and a higher proportion who are immigrants from less developed countries.

  • Trends in the Use of Highly Active Antiretroviral Therapy in Western Denmark 1996-2000

    by Søren Jensen-Fangel, Court Pederen, Carsten S. Larsen, Palle Tauris, Axel Møller, Niels Obel

    New antiretroviral drugs, expanding knowledge of their long-term toxic effects and the large number of patients with treatment failure have increased the demand for new strategies in the antiretroviral treatment of HIV-infected patients. The present study was conducted as part of the HIV Cohort Study in western Denmark to reveal trends in the use of antiretrovirals in the region. The cohort includes all patients attached to those centers treating HIV patients in western Denmark. A total of 537 patients who started highly active antiretroviral therapy (HAART) were included. The number of patients receiving HAART increased dramatically in 1996 and 1997 before leveling off, with 45-75 patients initiating treatment annually thereafter. Median follow-up time after initiation of HAART was 151 weeks. An estimated 45.1% of patients had the initial HAART regimen modified during the first year of follow-up. Side-effects and treatment failure were the main reasons for treatment modifications. Major new strategies implemented in the region in 1999 and 2000 included treatment with boosted protease inhibitors and non-nucleoside reverse transcriptase inhibitors.


  • The Insufficient Suppression of Viral Load by Saquinavir Hard Gel Is Reversible: A Retrospective Cohort Study

    by Søren Jensen-Fangel, Ole Kirk, Anders Blaxhult, Jan Gerstoft, Court Pedersen, Finn Trunk Black, Jens Dilling Lundgren, Neils Obel

    Purpose: To assess the effect of changing antiretroviral therapy in patients initially treated with saquinavir hard gel capsule (hgc). Method: A retrospective cohort study comparing the virological and immunological responses in antiretroviral-naïve patients initially treated with a regimen of saquinavir-hgc, zidovudine, and lamivudine, with patients receiving either ritonavir or indinavir on a background of zidovudine and lamivudine. Results: Twenty-nine patients starting with saquinavir-hgc as the protease inhibitor (PI) component were compared to 58 patients starting with ritonavir (n = 16) or indinavir (n = 42). Median follow-up time was 30 and 33 months, respectively. Twelve, 18, 24, and 30 months after starting a regimen including saquinavir-hgc, 72%, 50%, 4%, and 0% of patients still received this PI. At these time points, 35%, 24%, 59%, and 74% of the patients in the saquinavir group obtained an HIV-RNA <500 copies/mL compared to 76%, 72%, 66%, and 65% in the indinavir/ritonavir group. No significant difference in CD4 count between the two groups was observed. Conclusion: We found that saquinavir-hgc, in combination with nucleoside reverse transcriptase inhibitors, suppressed viral load insufficiently in HIV patients naïve to antiretroviral therapy. However, the suboptimal effect of saquinavir-hgc seems reversible after optimizing the antiretroviral regimen, at least for the short term.